Epitalon and Epithalamin Restore Night Melatonin in Aged Macaca mulatta Females
Background
Age-related decline in pineal gland function is a well-documented feature of mammalian aging, characterized by progressive suppression of nocturnal melatonin secretion — a hormone critical for regulating circadian rhythms, immune tone, and neuroendocrine balance. As melatonin falls with age, downstream dysregulation of multiple organ systems follows, yet no broadly accepted pharmacological strategy exists to selectively restore the aged pineal's output. Pineal peptide preparations represent a mechanistically distinct approach: short bioregulatory peptides hypothesized to act on pineal tissue to normalize secretory function. Whether these peptides could selectively rescue the blunted melatonin rhythm of aging without perturbing the intact rhythm of young animals was an open question requiring a controlled primate model.
Study Design
38 female Macaca mulatta were divided into two age cohorts: young (6–8 years, n = 18) and old (20–26 years, n = 20). Pineal function was assessed at baseline and after intramuscular administration of either epithalamin at 5 mg/animal/day for 10 consecutive days or epitalon at 10 µg/animal/day for 7–10 consecutive days, both developed at the St. Petersburg Institute of Bioregulation and Gerontology. Plasma melatonin concentration was the primary endpoint, sampled at multiple time points across the 24-hour cycle (documented measurement windows: 4 p.m., 9 p.m., 10 p.m., 3 a.m., and 4 a.m.) to capture the full diurnal rhythm profile.
Results
Baseline profiling confirmed that plasma melatonin in both age groups follows a high-amplitude diurnal rhythm, with a minimum at 4 p.m. and a peak spanning 10 p.m.–3 a.m. In old monkeys, mean diurnal melatonin concentration was reduced by 1.5–2 times relative to young animals, with statistically notable suppression at the 9 p.m., 10 p.m., 3 a.m., and 4 a.m. time points — the key nocturnal secretory window.
Administration of either epithalamin or epitalon induced a significant increase in night plasma melatonin specifically in old monkeys, restoring output toward levels characteristic of the younger cohort.
Critically, neither peptide preparation altered melatonin levels in young monkeys, demonstrating age-selectivity of the response. The effect was present across both peptide preparations despite their differing compositions and dosing durations (10 days for epithalamin vs. 7–10 days for epitalon), pointing to a shared mechanism of pineal restoration rather than a non-specific stimulatory effect.
Key Findings
- Mean diurnal melatonin in old monkeys was reduced 1.5–2 times vs. young animals at baseline.
- Epitalon (10 µg/animal/day, 7–10 days IM) significantly increased night melatonin in old monkeys.
- Epithalamin (5 mg/animal/day, 10 days IM) also significantly raised nocturnal melatonin in aged animals.
- Neither peptide altered melatonin levels in young (6–8 year) monkeys — response was age-selective.
- Melatonin suppression in aging was confirmed at 4 specific nocturnal time points: 9 p.m., 10 p.m., 3 a.m., 4 a.m.
Why It Matters
Selective restoration of nocturnal melatonin without disrupting the young pineal axis is a pharmacologically meaningful property — it suggests these peptides normalize rather than simply stimulate, reducing risk of overdrive in already-functional systems. For clinicians and researchers working on geriatric neuroendocrinology, this primate data provides stronger translational grounding than rodent studies alone. The 7–10 day intramuscular dosing window identified here for epitalon gives a concrete protocol anchor for designing human trials or structured self-experimentation cycles. Stack implications: because the response is age-gated, younger users may see little circadian benefit from epitalon, making chronological or biomarker-assessed pineal status a plausible stratification criterion before use.
TitrateLab articles covering Epitalon
Written by TitrateLab, separately from the study summarized above.
